Complete Pharmaceutical Traceability Compliance Guide: DSCSA, China Drug Traceability Standards, and EU FMD

Pharmaceutical traceability is the most strictly regulated and technically demanding traceability domain. All three major global pharmaceutical markets (China, US, EU) have established or are advancing mandatory pharmaceutical traceability regulatory frameworks. For pharmaceutical manufacturers, understanding and meeting these regulatory requirements is not only a compliance baseline but a responsibility to ensure patient medication safety. This article systematicallyorganize the compliance requirements and implementation key points of the three major pharmaceutical traceability standards.

China's Drug Informatization Traceability Standard System. Since 2018, the NMPA has gradually established a drug traceability standard system, with core documents including the "Guidelines for the Construction of Drug Informatization Traceability Systems," "Drug Traceability Code Coding Requirements," and "Basic Technical Requirements for Drug Traceability Systems." Key requirements: All drug manufacturers, distributors, and healthcare institutions must establish drug traceability systems enabling traceable sources and trackable destinations. Traceability codes use a unified coding standard, supporting both 1D barcodes (Code128C) and 2D codes (QR Code/DataMatrix) with QR codes recommended. Drug serialization requirements — every smallest sales unit (box/bottle/pouch) must carry a unique traceability code, with aggregation relationships established between cases (intermediate packaging) and pallets (bulk packaging). Traceability data must be uploaded to the collaborative service platform in prescribed formats and frequencies.

US DSCSA (Drug Supply Chain Security Act). DSCSA requires a fully electronic, interoperable traceability system by November 27, 2023. Core requirements: Product Identifier — each box/bottle of medication must include a standardized digital identifier containing NDC (drug code), serial number, lot number, and expiration date. Serialization — each smallest sales unit must have a unique serial number. Interoperable data exchange — supply chain participants must be able to securely and standardly exchange traceability data (EPCIS standard). Suspect product verification — distributors must be capable of verifying suspect products, confirming authenticity before deciding whether to release. Authorized trading partners — may only trade pharmaceuticals with authorized, registered trading partners. DSCSA violations can result in product seizure, import bans, and substantial fines.

EU FMD (Falsified Medicines Directive) and EMVS (European Medicines Verification System). EU FMD requires prescription drugs (and some OTC drugs) to carry safety features: a Unique Identifier (containing product code, serial number, lot number, expiration date) and tamper-evident packaging. Drugs are verified and decommissioned through the EU-level central database (EMVS).detailed workflow: Manufacturers upload drug UI data to EMVS; pharmacies/hospitals scan the drug code when dispensing; the system verifies drug authenticity in real time and "decommissions" the serial number in the database to prevent reuse. Each serial number can only be verified and decommissioned once; repeat scanning is automatically flagged as suspicious and triggers investigation.

Four Technical Challenges of Global Pharmaceutical Compliance. Challenge 1: Multi-standard compatibility — the three sets of standards from China, US, and EU differ in encoding formats, data models, andtransmission protocols, requiring a single system to simultaneously support multiple standard outputs and conversions. Challenge 2: Serialization management — serial numbers must be globally unique; multinational enterprises must manage serial number pools at the billion level, where any duplication or omission can lead to compliance failure. Challenge 3: Aggregation — precisely establishing unit→box→case→pallet hierarchical association relationships; association errors lead to inaccurate recall scope and broken traceability chains. Challenge 4: Data reporting — must submit data to different regulatory platforms according to each country's required data formats, transmission frequencies, and interface specifications. ZhiShuYun's pharmaceutical compliance solution supports a single master data source simultaneously outputting data formats meeting all three compliance requirements — China, US DSCSA, and EU FMD — dramatically reducing multi-standard management costs for multinational pharmaceutical enterprises.

Recommended Pharmaceutical Compliance Implementation Path. Phase 1 (Compliance assessment, 1-2 months): Clarify target market regulatory requirements, timelines, and scope of application; assess gaps in existing systems and processes. Phase 2 (Solution design, 2-3 months): Determine traceability code encoding scheme (GS1 standard strongly recommended), serial number management strategy (centralized vs distributed), data exchange architecture (data interoperabilityplan with CMOs, 3PLs, and other partners). Phase 3 (System implementation, 3-6 months): Production line coding modification, packaging line serialization and aggregation system launch, ERP/WMS data integration, regulatory platform data interface integration testing. Phase 4 (Go-live validation, 2-3 months): Small-batch trial run, regulatory submission data validation, full-category rollout. Phase 5 (Continuous compliance): Monitor regulatory updates,regular audit data integrity, respond to surprise inspections. Complete implementation cycle is typically 9-18 months; it is recommended to start at least 12 months before the regulatory deadline.